Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have redefined the management of obesity and type 2 diabetes mellitus, producing sustained and clinically meaningful reductions in total body weight alongside significant cardiometabolic benefits. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.